Search research articles
Contact Us
Filters
Showing results (51-60 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Frontiers in Oncology
|
June 3, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models
Yvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Journal of Molecular Diagnostics : JMD
|
May 6, 2019
Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements
Hua-Jun He, Erica V Stein, Yves Konigshofer, et al.
JCO Precision Oncology
|
April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Alice P Chen, Shivaani Kummar, Nancy Moore, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2020
Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H
April K S Salama, Shuli Li, Erin R Macrae, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
Frontiers in Oncology
|
June 3, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models
Yvonne A Evrard, Sergio Y Alcoser, Michael Mullendore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
The Journal of Molecular Diagnostics : JMD
|
May 6, 2019
Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements
Hua-Jun He, Erica V Stein, Yves Konigshofer, et al.
JCO Precision Oncology
|
April 30, 2021
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
Alice P Chen, Shivaani Kummar, Nancy Moore, et al.
Page
of 9